Aldehyde Dehydrogenase Activity Distinguishes Leukemia Stem Cells from Normal Hematopoietic Stem Cells in Acute Myeloid Leukemia

Case ID:

C11237

Using the methods of the present invention, intermediate (int) levels of aldehyde dehydrogenase (ALDH) activity reliably distinguished leukemic CD34+CD38? cells capable of engrafting immunodeficient mice, from residual normal hematopoietic stem cells that exhibited relatively higher ALDH activity. Minimal residual disease (MRD) detected during complete remission was enriched for the CD34+CD38?ALDHint leukemic cells, and the presence of these cells after therapy highly correlated with subsequent clinical relapse. The methods of the present invention can distinguish normal from leukemic CD34+CD38? cells, and identifies those AML cells associated with relapse. Methods of prediction of relapse of AML patients and methods of treatment are also provided.

Patent Information:

Title	App Type	Country	Serial No.	Patent No.	File Date	Issued Date	Expire Date	Patent Status
Aldehyde Dehydrogenase Activity Distinguishes Leukemia Stem Cells from Normal Hematopoietic Stem Cells in Acute Myeloid Leukemia	ORD: Ordinary Utility	United States	13/625,369	9,012,215	9/24/2012	4/21/2015	9/24/2032	Granted

Direct Link:

https://jhu.technologypublisher.com/technology/24649

Inventors:

Category(s):

Clinical and Disease Specializations, Clinical and Disease Specializations > Hematology, Clinical and Disease Specializations > Oncology > Acute Myeloid Leukemia, Clinical and Disease Specializations > Oncology > Hematologic Malignancies, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology,

Get custom alerts for techs in these categories/from these inventors:

Subscribe for JHTV Updates

For Information, Contact:

Nakisha Holder

nickki@jhu.edu

410-614-0300

Save This Technology:

Bookmark this page

Download as PDF